Vigil Neuroscience, Inc.
Funding rounds
3 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2022 | $75 M | No. 3 | $50 to $250 million | equity, options | SEC | |
| Aug 2021 | $90 M | No. 2 | $50 to $250 million | equity | SEC | |
| Sep 2020 | $50 M | No. 1 | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Vigil Neuroscience, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2022).
SEC Form D · Aug 2022
The industry group it chose in its notices: Other.
SEC Form D · Aug 2022
That is all the official record says: Vigil Neuroscience, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
18 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Alexandria Venture Investments, LLC | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| Amgen Inc | Company | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| Atlas Venture Associates Opportunity I, LLC | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| Atlas Venture Associates Opportunity I, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| Atlas Venture Associates XII, LLC | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| Atlas Venture Associates XII, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| Atlas Venture Fund XII, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| Atlas Venture Opportunity Fund I, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| Cormorant Asset Management, LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| Cormorant Global Healthcare Master Fund, LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| Cormorant Private Healthcare Fund IV LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| Northpond Ventures GP II, LLC | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| Northpond Ventures GP, LLC | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| Northpond Ventures II, LP | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| Northpond Ventures, LP | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| Vida Ventures GP III, L.L.C. | Venture capital | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| Vida Ventures III-A, L.P. | Venture capital | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
| Vida Ventures III, L.P. | Venture capital | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2022) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 19 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Christopher Verni | Executive officer | Aug 2022 |
| Evan Thackaberry | Executive officer | Aug 2022 |
| Ivana Magovcevic-Liebisch | Executive officer | Aug 2022 |
| Jennifer Ziolkowski | Executive officer | Aug 2022 |
| Spyros Papapetropoulos | Executive officer | Aug 2022 |
| Bruce Booth | Director | Aug 2022 |
| Cheryl Blanchard | Director | Aug 2022 |
| Gerhard Koenig | Director | Aug 2022 |
| Ivana Magovcevic-Liebisch | Director | Aug 2022 |
| Mary Thistle | Director | Aug 2022 |
| Shaan Gandhi | Director | Aug 2022 |
| Stefan Vitorovic | Director | Aug 2022 |
| Suzanne Bruhn | Director | Aug 2022 |
| Cheryl Blanchard, Ph. D. | Director | Aug 2021 |
| Clay Thorp | Director | Aug 2021 |